Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 30:11:258.
doi: 10.1186/1471-2334-11-258.

Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township

Affiliations

Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township

Stephen D Lawn et al. BMC Infect Dis. .

Abstract

Background: Delays in the initiation of antiretroviral therapy (ART) in patients with HIV-associated tuberculosis (TB) are associated with increased mortality risk. We examined the timing of ART among patients receiving care provided by non-integrated TB and ART services in Cape Town, South Africa.

Methods: In an observational cohort study, we determined the overall time delay between starting treatment for TB and starting ART in patients treated in Gugulethu township between 2002 and 2008. For patients referred from TB clinics to the separate ART clinic, we quantified and identified risk factors associated with the two component delays between starting TB treatment, enrolment in the ART clinic and subsequent initiation of ART.

Results: Among 893 TB patients studied (median CD4 count, 81 cells/μL), the delay between starting TB treatment and starting ART was prolonged (median, 95 days; IQR = 49-155). Delays were shorter in more recent calendar periods and among those with lower CD4 cell counts. However, the median delay was almost three-fold longer for patients referred from separate TB clinics compared to patients whose TB was diagnosed in the ART clinic (116 days versus 41 days, respectively; P < 0.001). In the most recent calendar period, the proportions of patients with CD4 cell counts < 50 cells/μL who started ART within 4 weeks of TB diagnosis were 11.1% for patients referred from TB clinics compared to 54.6% of patients with TB diagnosed in the ART service (P < 0.001).

Conclusions: Delays in starting ART were prolonged, especially for patients referred from separate TB clinics. Non-integration of TB and ART services is likely to be a substantial obstacle to timely initiation of ART.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Conceptual diagram showing the component time periods (α1, α2 and β) between tuberculosis (TB) diagnosis and starting antiretroviral therapy (ART) for patients with TB diagnosed either in a TB clinic or in the ART clinic.
Figure 2
Figure 2
Time to event analysis showing the cumulative proportion of patients starting antiretroviral therapy (ART) during tuberculosis (TB) treatment. Data are stratified according to whether the patients were referred from a TB clinic or whether the TB was diagnosed in the ART clinic.

References

    1. World Health Organization. Global tuberculosis control. A short update to the 2009 report. WHO, Geneva; 2009. http://www.who.int/tb/publications/global_report/2009/update/tbu_9.pdf Accessed on 01.03.10.
    1. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis. 2009;13:6–16. - PubMed
    1. Lawn SD, Kranzer K, Wood R. Antiretroviral Therapy for Control of the HIV-associated Tuberculosis Epidemic in Resource-Limited Settings. Clin Chest Med. 2009;30:685–699. doi: 10.1016/j.ccm.2009.08.010. - DOI - PMC - PubMed
    1. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis. 2011;24:34–42. doi: 10.1097/QCO.0b013e3283420f76. - DOI - PMC - PubMed
    1. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006;43:42–46. doi: 10.1097/01.qai.0000230521.86964.86. - DOI - PubMed

Publication types

Substances